Clinical trial will enroll more than 3,000 patients across 75 participating hospitals in U.S. DETROIT, Dec. 6, 2022 /PRNewswire/ — Henry Ford Health will be spearheading a multi-center, first-of-its-kind national clinical trial dubbed the “CORRAL-AF IDE” study for an innovative left atrial appendage occlusion device known as the LAmbre™ Plus Left Atrial […]
Other News
FLEX Vessel Prep 12 Month AV Registry Data and 12 Month Belong PAD Data Shows Benefit to Micro-incisions Before Balloon or DCB Treatment
MINNEAPOLIS, Dec. 6, 2022 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced data presented at the VEITH Symposium, Nov. 15-19th, New York, New York. Overall, the data presented demonstrated that FLEX Vessel […]
BaleDoneen Method Study Identifies New Strategy to Prevent Heart Attacks, Strokes and Chronic Illness: Stopping Oxidative Stress
SPOKANE, Wash., Dec. 6, 2022 /PRNewswire/ — Atherosclerosis starts when cholesterol becomes trapped in the artery wall, sparking inflammation that could lead to a heart attack, stroke, or other chronic illnesses. The most common trigger is oxidative stress, which has been implicated in many chronic diseases, according to new peer-reviewed research published Frontiers […]
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, December 6, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the second closing and completion of its Series C […]
BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology
Clinical abstract focuses on value of PURE EP™’s and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation Westport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization […]
Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today […]
Enzyvant Announces Merger with Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology CARY, N.C., Dec. 06, 2022 (GLOBE NEWSWIRE) — Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of Sumitovant Biopharma Ltd., today announced a merger to form a biopharmaceutical […]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Alexander (Bo) Cumbo; Chief Administrative […]
Cleerly Hires Udo Hoffmann, MD, MPH as Chief Scientific Officer
Cardiovascular clinical trial expert brings AI imaging experience to lead research efforts NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Udo Hoffmann, MD, MPH, as chief scientific officer. In this role, Dr. Hoffmann will oversee Cleerly’s large-scale research efforts, including […]
Limflow Appoints Mike Mathias as Vice President, Commercial Operations
PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Mike Mathias as Vice President of Commercial Operations. Mr. Mathias has spent his 30-year career successfully leading sales organizations […]



